Articles related to BIPOLAR DISORDER

The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

A middle-aged woman with a four-year bipolar disorder diagnosis continued deteriorating despite psychiatric treatment until clinical reassessment pointed toward anti-NMDA receptor encephalitis, an autoimmune condition whose psychiatric prodrome frequently delays correct diagnosis.

A Rhode Island court denied summary judgment in an informed consent suit after a patient developed permanent tardive dyskinesia following an intra-class antipsychotic switch.

A meta-analysis of 285 studies found lifetime psychosis in over half of patients with bipolar disorder and comorbid schizophrenia in 8%, with substantial differences between bipolar I and bipolar II subtypes.

The study authors concluded, “These findings further our understanding of shared and distinct neural mechanisms underlying mood disorders and assist in differential diagnosis, thereby guiding more accurate treatment strategies.”

“A fully oral, inexpensive NMDA-AMPA modulation strategy may offer a practical alternative for patients with the bipolar obsessive-compulsive disorder phenotype who respond poorly to conventional approaches.” — Ngo Cheung, MBBS